Antifungals for Candidosis Treatment

Abstract

The available treatments for oral candidosis have proved to be more effi cacious with the use of new and known antifungal drugs. The success of these is directly related to the correct diagnosis, identifi cation, and correction of etiological factors and the commitment of the patient. In the absence of some of these factors, the antifungal therapy results only in a brief relief from disease, triggering relapses. This chapter presents the main drugs used in the treatment of oral and oropharyngeal candidosis, their functioning in the human body, and their mechanism of action in the destruction of the pathogenic agent.

Comparison of the pharmacokinetic profiles of two different amphotericin B formulations in healthy dogs

“…Moreover, several reports have demonstrated that particle sizes of liposomes are critical factors in the elimination process of the liposomal drugs and liposomes with small particle size (100 nm) provide longer drug elimination half‐life (Ait‐Oudhia, Mager, & Straubinger, ; Azanzo, Sadada, & Reis, ; Sercombe et al., ). While the exact metabolic pathways and elimination of amphotericin B have been insufficiently elucidated (Gregio, Veiga, Rinaldi, & Bettega, ), the long elimination half‐life of liposomal amphotericin B suggests that its elimination mechanism differs from that amphotericin B deoxycholate. In particular, the chemical properties and physical form of liposomal amphotericin B (Adler‐Moore, Gangneux, & Pappas, ) may provide advantages based on the extended elimination half‐life of the drug.…”